

DECIPHER PROSTATE BIOPSY

WHAT IS THE DECIPHER TEST?

Decipher is a tumor-based test that provides genomic information to help you and your physician make decisions about your care



DECIPHER BIOPSY

- Performed on your prostate biopsy tissue diagnosed as positive for cancer
- Helps determine which men may be suitable candidates for active surveillance, who may need local therapy, and who may need intensified therapy



ACCESS FOR ALL PATIENTS

- Covered by Medicare
- Covered by select private insurers
- Generous financial assistance program for patients - Decipher Assist

Contact the Decipher Customer Support Team at 1.888.792.1601 or cs@decipherbio.com



Decipher Biosciences
Information for Life

To learn more about Decipher, contact the Decipher Customer Support Team at 1.888.792.1601 or cs@decipherbio.com

Copyright © 2020 Decipher Biosciences, Inc.
Testing is performed by Decipher Corp., a Decipher Biosciences company

DECIPHER PROSTATE BIOPSY

AFTER POSITIVE BIOPSY



Learn more about
your tumor.

Decipher Biopsy helps you and your doctor decide next steps in your prostate cancer care

DECIPHER PROSTATE BIOPSY

Decipher is a genomic test that is performed on tumor tissue from your positive prostate biopsy.

EVERY TUMOR IS UNIQUE

Decipher provides important information about the underlying biology of your tumor that is not always evident



This test is covered by Medicare and select private insurers. We have a generous financial aid program, Decipher Assist, for qualified patients.

DECIPHER PROSTATE GENOMIC RISK



PATIENT MANAGEMENT RECOMMENDATIONS

Unfavorable prognosis – may not be suitable for active surveillance and may benefit from intensification with multi-modal therapy¹⁻⁴

Favorable prognosis – may be suitable for active surveillance and may have excellent outcomes with local therapy alone, such as surgery or radiotherapy¹⁻⁴

THE DECIPHER TEST CAN HELP YOU ANSWER THE FOLLOWING QUESTIONS:

- Is active surveillance with PSA monitoring sufficient for me?
- If I receive radiation therapy, will I also need to receive hormone therapy?



Contact your doctor to find out how Decipher might play a role in your treatment planning or contact:

Decipher Customer Support Team
» 1.888.792.1601 or
» cs@decipherbio.com

References

1. Klein, E. A. et al. Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk. *Urology* (2016). doi:10.1016/j.urology.2016.01.012
2. Berlin, A. et al. Genomic classifier for guiding treatment of intermediate-risk prostate cancers to dose-escalated image-

- guided radiotherapy without hormone therapy. *Int. J. Radiat. Oncol.* (2018). doi:10.1016/j.ijrobp.2018.08.030
3. Nguyen, P. L. et al. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. *Eur. Urol.* (2017). doi:10.1016/j.

- eururo.2017.05.009
4. Kim, H. L. et al. Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. *Prostate Cancer Prostatic Dis.* (2018). doi:10.1038/s41391-018-0101-6